DE69519921D1 - Imidazolidin-derivate und ihre verwendung - Google Patents

Imidazolidin-derivate und ihre verwendung

Info

Publication number
DE69519921D1
DE69519921D1 DE69519921T DE69519921T DE69519921D1 DE 69519921 D1 DE69519921 D1 DE 69519921D1 DE 69519921 T DE69519921 T DE 69519921T DE 69519921 T DE69519921 T DE 69519921T DE 69519921 D1 DE69519921 D1 DE 69519921D1
Authority
DE
Germany
Prior art keywords
groups
group
alkyl
esterified
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69519921T
Other languages
English (en)
Other versions
DE69519921T2 (de
Inventor
Harukazu Fukami
Motoo Sumida
Shinjiro Niwata
Saki Kakutani
Masayuki Saitoh
Hiroshi Shibata
Yoshinobu Kiso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of DE69519921D1 publication Critical patent/DE69519921D1/de
Application granted granted Critical
Publication of DE69519921T2 publication Critical patent/DE69519921T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/80Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86Oxygen and sulfur atoms, e.g. thiohydantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
DE69519921T 1994-07-29 1995-07-26 Imidazolidin-derivate und ihre verwendung Expired - Fee Related DE69519921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20786794 1994-07-29
JP33370694 1994-12-07
PCT/JP1995/001485 WO1996004248A1 (fr) 1994-07-29 1995-07-26 Derives d'imidazolidine et son utilisation

Publications (2)

Publication Number Publication Date
DE69519921D1 true DE69519921D1 (de) 2001-02-22
DE69519921T2 DE69519921T2 (de) 2001-06-13

Family

ID=26516513

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69519921T Expired - Fee Related DE69519921T2 (de) 1994-07-29 1995-07-26 Imidazolidin-derivate und ihre verwendung

Country Status (7)

Country Link
US (1) US5691335A (de)
EP (1) EP0721944B1 (de)
AT (1) ATE198743T1 (de)
AU (1) AU3086095A (de)
DE (1) DE69519921T2 (de)
ES (1) ES2155134T3 (de)
WO (1) WO1996004248A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912261A (en) * 1994-12-20 1999-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Carboxyalkyl heterocyclic derivatives
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
JPH10182460A (ja) * 1996-12-27 1998-07-07 Nippon Zoki Pharmaceut Co Ltd 3−デオキシグルコソン生成阻害剤
KR100903531B1 (ko) 1998-07-15 2009-06-23 데이진 가부시키가이샤 티오벤즈이미다졸 유도체
US20050267148A1 (en) * 1998-07-15 2005-12-01 Teijin Limited Benzimidazole derivative
KR100381214B1 (ko) * 1998-08-10 2003-09-22 주식회사 엘지생명과학 항암제로유용한이미다졸리딘-2,4-디온유도체및그의제조방법
KR20010074838A (ko) * 1998-08-20 2001-08-09 요시다 쇼지 안 순환 장해의 예방 또는 치료제
KR20010089168A (ko) * 1998-08-21 2001-09-29 도리이 신이치로 퀴나졸린 유도체 및 이의 약제학적 용도
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
US6432978B1 (en) * 1998-12-01 2002-08-13 Meiji Seika Kaisha, Ltd. SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities
EP1224945A4 (de) * 1999-10-25 2004-08-18 Senju Pharma Co Mittel zur linderung der ziliarmuskelspannung
WO2001032214A1 (fr) 1999-11-01 2001-05-10 Suntory Limited Inhibiteurs diriges contre le depot de lipides dans les vaisseaux, contenant des substances inhibant la chymase
US6300503B1 (en) * 1999-12-17 2001-10-09 Dixie Chemical Company Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
HUP0201282A3 (en) * 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient
US6500835B2 (en) 2000-02-22 2002-12-31 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
HUP0201287A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for various eosinphilia-related diseases containing quinazoline derivative chymase inhibitors as the active ingredient
JP4711523B2 (ja) 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
JPWO2002083649A1 (ja) * 2001-04-11 2004-08-05 千寿製薬株式会社 新規イミダゾリジンジオン誘導体およびその医薬用途
KR20050026019A (ko) * 2002-07-30 2005-03-14 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 동맥-정맥 이식 부전의 예방 및/또는 치료를 위한키마아제 저해제의 용도
WO2004031160A2 (fr) * 2002-10-04 2004-04-15 Laboratoires Fournier S.A. Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
FR2845383B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845384B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
KR101187693B1 (ko) 2003-05-09 2012-10-05 도레이 카부시키가이샤 신장질환의 치료 또는 예방제
US7361767B2 (en) * 2003-11-14 2008-04-22 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
AU2004305075A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7544756B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
HUE027894T2 (en) 2006-03-27 2016-11-28 Univ California An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases
SG10201408699TA (en) 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
EP2620432A3 (de) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoinverbindungen
JP5587914B2 (ja) 2009-01-30 2014-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング キマーゼ阻害剤として有用なアザキナゾリンジオン
EP3124481B1 (de) 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgenrezeptormodulatoren und verwendungen davon
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3066096A1 (de) * 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile als chymase inhibitoren
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3468956B1 (de) * 2016-06-14 2021-03-03 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one als apj agonisten
WO2017218617A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
WO2019023448A1 (en) * 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1207391B (de) * 1962-05-30 1965-12-23 Degussa Verfahren zur Herstellung von 3-Benzoyl-5, 5-dimethylhydantoinen
US4166124A (en) * 1970-05-15 1979-08-28 U.S. Philips Corporation Insecticidal 2,6-dihalobenzoyl urea derivatives
JPS5371073A (en) * 1976-12-03 1978-06-24 Sumitomo Chem Co Ltd 1-cyclic alkyl carbonyl-3(3,5-dihalogenophenyl)hydantoin derivs., process fo r their preparation and fungicides for agriculture and horti culture contg. the same as active constituents
JPS5855468A (ja) * 1981-09-25 1983-04-01 Sumitomo Chem Co Ltd 5−クロロヒダントイン誘導体、その製造法およびそれを有効成分として含有する殺虫剤
US4474796A (en) * 1983-02-04 1984-10-02 Sumitomo Chemical Company, Limited Insecticidal substituted hydantoins
JPH068281B2 (ja) * 1985-09-19 1994-02-02 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とするアルド−スレダクタ−ゼ阻害剤

Also Published As

Publication number Publication date
ATE198743T1 (de) 2001-02-15
AU3086095A (en) 1996-03-04
EP0721944A1 (de) 1996-07-17
US5691335A (en) 1997-11-25
DE69519921T2 (de) 2001-06-13
EP0721944A4 (de) 1997-01-02
ES2155134T3 (es) 2001-05-01
WO1996004248A1 (fr) 1996-02-15
EP0721944B1 (de) 2001-01-17

Similar Documents

Publication Publication Date Title
DE69519921D1 (de) Imidazolidin-derivate und ihre verwendung
DE69716226D1 (de) Difluoroprostaglandin-Derivate und ihre Anwendung
EP1070710A3 (de) Dithiolan Derivate, deren Herstellung und deren therapeutischer Wirkung
IL184539A (en) The heteroaryl sulfonamide compounds, their preparations and their uses
DE69738245D1 (de) 1,2-Diphenylpyrrol-Derivate, ihre Herstellung und therapeutische Verwendung
EP0795548A4 (de) Chinazozin derivate und deren verwendung
NO174050C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive benzopyranforbindelser
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
EP0549796A4 (en) Diphenylpiperazine derivative and drug for circulatory organ containing the same
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
BRPI0408675A (pt) derivados de talidomida solúveis em água
DE60016384D1 (de) Chondrogonese promotoren und indolin-2-on derivate
ATE360423T1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
DE69713648T2 (de) Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten
IT1276161B1 (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
ATE241985T1 (de) Therapeutisches mittel zur behandlung von nierenerkrankungen
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAICHI SUNTORY PHARMA CO., LTD., TOKIO/TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI ASUBIO PHARMA CO., LTD., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee